Weekly paclitaxel or nab-paclitaxel with pembrolizumab and mirabegron for recurrent ovarian cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase II trial giving participants weekly paclitaxel or nab-paclitaxel together with pembrolizumab every 21 days and daily mirabegron to see if the combination reduces tumor size and is tolerable. Eligible adults have relapsed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with measurable disease and generally good performance status. Participants will attend clinic visits about every two months for imaging, safety monitoring, and will keep a symptom diary. The main outcomes are change in tumor burden by RECIST 1.1 and the types and frequency of treatment-related adverse events.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Has provided documented informed consent for the study.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Has histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
* Has received a front line platinum-based regimen (administered via either intravenous or intraperitoneal route) per local standard of care or treatment guideline following the primary or interval debulking surgery with documented disease recurrence (note: Maintenance treatment following the front line treatment is permitted and counted together as part of the front line treatment).
* Has a platinum-free interval (PFI) of \< 12 months if the last regimen received is a platinum-based, or a treatment-free interval (TFI) of \< 12 months if the last regimen received is a non-platinum-based.
* Has measurable disease at baseline based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
* Has a life expectancy of ≥12 weeks.
* Has provided a tumor tissue sample either collected from prior cytoreductive surgery or fresh newly obtained tumor tissue at screening.
* Has adequate organ function.
* Has not recovered from AEs to ≤ Grade 1 or prior treatment level due to a previously administered agent.

Exclusion Criteria:

* Has nonepithelial cancers, borderline tumors, mucinous, seromucinous that is predominantly mucinous, malignant Brenner's tumor and undifferentiated carcinoma.
* Has received prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated antigen-4 \[CTLA-4\], tumor necrosis factor receptors OX-40 or CD137).
* Has received prior systemic anticancer therapy including radiation therapy or maintenance therapy within 4 weeks before enrollment.
* Has severe hypersensitivity (≥Grade 3) or uncontrolled hypertension to paclitaxel/nab-paclitaxel, pembrolizumab, mirabegron and any of their excipients.
* Has undergone major surgery within 3 weeks before enrollment or has complications/sequelae that have not yet recovered.
* Has a known additional malignancy that progressed or required active treatment within the last 5 years.
* Is pregnant or breastfeeding.
* Has a history of allogenic tissue/solid organ transplant.
* Has a history of thrombotic disorders, hemorrhage, hemoptysis, or active gastrointestinal bleeding within 6 months before enrollment.
* Has a history of active autoimmune disease.
* Has an active infection requiring systemic therapy.
* Has a history of human immunodeficiency virus (HIV) infection.
* Has a history of Hepatitis B or C virus infection.
* Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study.
* Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.

Where it's running

• Obstetrics and Gynecology Hospital of Fudan University
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Cao, Doctor
• Email: caokankan@126.com
• Phone: 86 13301971027

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• EBNK-001 allogeneic NK cell therapy with low-dose IL-15, with or without pembrolizumab, for advanced solid tumors

  This treatment tests an off-the-shelf NK cell product (EBNK-001) given with low-dose IL-15, either alone or with pembrolizumab, in adults with advanced or metastatic solid tumors who have exhausted standard options.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410676

• Zanzalintinib plus pembrolizumab for select advanced soft-tissue sarcomas

  This trial will test whether combining zanzalintinib with pembrolizumab can help control certain advanced or metastatic soft-tissue sarcomas in adults.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07283731

• Moderate-dose radiotherapy combined with Pembrolizumab for liver cancer with blood vessel blockage

  This study is testing if combining a specific type of radiation therapy with the immunotherapy drug Pembrolizumab can help people with liver cancer that has blocked blood vessels feel better and live longer.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06389422

• Combining targeted therapies for solid tumors using CDK4/6 inhibitors and anti-VEGF agents

  This study is testing if combining two cancer treatments, Palbociclib and Bevacizumab, can help people with solid tumors like colorectal, breast, and ovarian cancers feel better and respond better to treatment.

  Recruiting at 2 sites Phase 1 Lebanese University · Tripoli, North Lebanon and 1 other locations · NCT06307249

• Combining Pembrolizumab with Chemotherapy for Advanced Head and Neck Cancer

  This study is testing whether adding a drug called pembrolizumab to standard chemotherapy can help people with advanced head and neck cancer respond better to treatment.

  Recruiting Phase 3 Beijing Tongren Hospital · Beijing, Beijing Municipality · NCT06102395

• Combining pembrolizumab, bevacizumab, and cyclophosphamide for treating ovarian cancer with minimal residual disease

  This study is testing a new combination of three drugs to see if it can help women with high-grade ovarian cancer who have very little disease left after treatment live longer without their cancer getting worse.

  Recruiting Phase 2 M.D. Anderson Cancer Center · New York, New York and 1 other locations · NCT06083844

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.